• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Merck

Merck

Merck & Co Inc MRK 4 Star

Last Price$59.70Day Change (%)1.24%
Open Price$59.09Day Change ($)0.73
Day Range58.87–59.7852-Week Range52.49–63.62

As of Wed 5/27/2015 1:01:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma

    Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma

  2. Merck Profit Pressured by Financing for Sigma-Aldrich Deal

    Merck Profit Pressured by Financing for Sigma-Aldrich Deal

  3. Research and Markets: European Liquid Chromatography Reagents Market Report 2015 - Column & Planar Chromatography Reagents

    Research and Markets: European Liquid Chromatography Reagents Market Report 2015 - Column & Planar Chromatography Reagents

  4. New Push Ties Cost of Drugs to How Well They Work

    New Push Ties Cost of Drugs to How Well They Work

  5. Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

    Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

  6. Research and Markets: Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

    Research and Markets: Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

  7. Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases

    Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases

  8. Merck shares up 4.5% as company beats profit, sales estimates and raises outlook

    Merck shares up 4.5% as company beats profit, sales estimates and raises outlook

  9. 4 Companies Leading the Next Wave of Cancer-Drug Innovation

    First movers and firms that provide combination therapies represent the best investment opportunities in the immuno-oncology market, says Morningstar's Damien Conover.

  10. Market Undervalues Merck ’s Pipeline

    New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.